**Shuxuetong injection protects cerebral microvascular endothelial cells against oxygen-glucose deprivation reperfusion**

Zuo-Yan Sun1,2, Fu-Jiang Wang1, Hong Guo1, Lu Chen1, Li-Juan Chai3, Rui-Lin Li1, Li-Min Hu1, Hong Wang1, Shao-Xia Wang4,4,4,4
1 Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
2 Department of Pharmacy, Linyi Central Hospital, Linyi, Shandong Province, China
3 School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
4 Key Laboratory of Pharmacology of Traditional Chinese Medical Formula, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China

**Funding:** This study was supported in part by the National Natural Science Foundation of China, No. 81573644 (to LMH), 81573733 (to SWX); the Tianjin 131 Innovative Team Project, China (to HW); the National Major Science and Technology Project of China, No. 2012ZX09101201-004 (to SWX); the Science and Technology Plan Project of Tianjin of China, No. 16PTSYJC00120 (to LMH); the Applied Foundation and Frontier Technology Research Program of Tianjin of China (General Project), No. 14JCUI228900 (to SXW); the National International Science and Technology Cooperation Project of China, No. 2015DFA30430 (to HW); the Key Program of the National Science Foundation of Tianjin of China, No. 16JCZDJC3300 (to HW); the Scientific Research and Technology Development Plan Project of Guangxi Zhuang Autonomous Region of China, No. 14125008-2-5 (to SXW).

**Graphical Abstract**

**Protective effects of Shuxuetong (SXT) injection on cerebral microvascular endothelial cells induced by oxygen-glucose deprivation/reperfusion (OGD/R)**

- Attenuated BBB dysfunction
- Attenuated inflammation injury
- Decrease the expression of VEGF and p-ERK1/2
- Reduced the ROS and mitochondrial peroxide production

**Abstract**

*Shuxuetong* injection composed of leech (*Hirudo nipponica* Whitman) and earthworm (*Pheretima aspergillum*) has been used for the clinical treatment of acute stroke for many years in China. However, the precise neuroprotective mechanism of *Shuxuetong* injection remains poorly understood. Here, cerebral microvascular endothelial cells (bEnd.3) were incubated in glucose-free Dulbecco’s modified Eagle’s medium containing 95% N2/5% CO2 for 6 hours, followed by high-glucose medium containing 95% O2 and 5% CO2 for 18 hours to establish an oxygen-glucose deprivation/reperfusion model. This *in vitro* cell model was administered *Shuxuetong* injection at 1/32, 1/64, and 1/128 concentrations (diluted 32-, 64-, and 128-times). Cell Counting Kit-8 assay was used to evaluate cell viability. A fluorescence method was also used to measure mitochondrial superoxide production. A fluorescence probe was used to measure transepithelial resistance and examine integrity of monolayer cells. The fluorescent isothiocyanate-dextran test was performed to examine blood-brain barrier permeability. Real-time reverse transcription polymerase chain reaction was performed to analyze mRNA expression levels of tumor necrosis factor alpha, interleukin-1β, interleukin-6, and inducible nitric oxide synthase. Western blot assay was performed to analyze expression of caspase-3, intercellular adhesion molecule 1, vascular cell adhesion molecule 1, claudin-5, occludin, and zonula occludens-1. Our results show that *Shuxuetong* injection increases bEnd.3 cell viability and B-cell lymphoma 2 expression, reduces cleaved caspase-3 expression, inhibits production of reactive oxygen species and mitochondrial superoxide, suppresses expression of tumor necrosis factor alpha, interleukin-1β, interleukin-6, inducible nitric oxide synthase mRNA, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1, markedly increases transepithelial resistance, decreases blood-brain barrier permeability, upregulates claudin-5, occludin, and zona occludens-1 expression, reduces nuclear factor-xB p65 and vascular endothelial growth factor expression, and reduces I kappa B alpha, extracellular signal-regulated protein kinase 1/2, and I kappa B kinase phosphorylation levels. Overall, these findings suggest that *Shuxuetong* injection has protective effects on brain microvascular endothelial cells after oxygen-glucose deprivation/reperfusion. Moreover, its protective effect is associated with reduction of mitochondrial superoxide production, inhibition of the inflammatory response, and inhibition of vascular endothelial growth factor, extracellular signal-regulated protein kinase 1/2, and the nuclear factor-xB p65 signaling pathway.

**Key Words:** nerve regeneration; *Shuxuetong* injection; brain microvascular endothelial cells; oxygen-glucose deprivation/reperfusion; tight junction proteins; mitochondrial function; inflammatory factors; blood-brain barrier; neuroprotection; neural regeneration

**Chinese Library Classification No.** R453; R364; Q26
Introduction
Ischemic stroke accounts for 75–80% of all strokes and is a leading cause of death and disability. Ischemic stroke is induced by clogged blood vessels that leave target organs at risk of cellular death (Johnston et al., 2009; Roger et al., 2012). Moreover, ischemic cerebral injury is accompanied by severe brain dysfunction. In the early phase, insufficient supply of oxygen, glucose, and energy to damaged regions causes rapid cell injury with a large amount of reactive oxygen species produced in mitochondria (Suchadolskiene et al., 2014). Simultaneously, oxygen-poor reactive oxygen species overload can quickly aggravate mitochondrial damage and mitochondrial oxidative phosphorylation, which induces free lipid accumulation (Adibhatla and Hatcher, 2008). This pathological cascade reaction eventually leads to inflammatory reaction, blood-brain barrier (BBB) breakdown, apoptosis, and cell death within minutes (Xing et al., 2012; Zhang et al., 2017).

To date, tissue plasminogen activator is the only effective treatment for rescuing ischemic brain tissue. However, its application is restricted because of limitations, such as a narrow therapeutic window and risk of cerebral hemorrhage, (Moskowitz et al., 2010). Thus, developing new drugs for acute stroke is urgent. Because of failed clinical trials that centered on neurons, more attention is now being given to non-neuronal cell types (Barreto et al., 2011). Consequently, there is much attention on brain microvascular endothelial cells because of their importance in maintaining integrity of BBB structure and function, which is a promising target for intervention in cerebral ischemic injury (Watanabe et al., 2013). Not surprisingly, brain microvascular endothelial cells are considered to play a central role in BBB function, and are responsible for maintaining BBB integrity through expression of tight junction proteins (Yang and Rosenberg, 2011). Occludin, claudin-5, and zonula occludens-1 (ZO-1) are the major proteins associated with BBB function and structure (Gerriets et al., 2009; Tuttolomondo et al., 2014; Krueger et al., 2015). Nonetheless, primary culture of brain microvascular endothelial cells has drawbacks, namely, a tedious research process, cell contamination, and slow growth. The cell line, bEnd.3, has the basic characteristics of brain microvascular endothelial cells (He et al., 2010; Yang and Rosenberg, 2011), and advantages such as a short growth cycle and rapid cell proliferation. Further, expression of BBB characteristics was also detected with bEnd.3 cells. Accordingly, this cell line can replace primary cells for culture (He et al., 2010; Yang and Rosenberg, 2011). Previous studies have suggested that excessive reactive oxygen species and inflammation are main factors in vascular BBB lesions (Kaur and Ling, 2008; da Fonseca et al., 2014; Kawabori and Yenari, 2015). In addition, several signaling molecules such as extracellular signal regulated protein kinase 1/2 (ERK1/2), vascular endothelial growth factor (VEGF), and nuclear factor kappa-B (NF-κB) are involved in tight junction disruption and BBB breakdown (Beker et al., 2015; Hung et al., 2015; Wang et al., 2015).

Shuxuetong injection is a standardized drug applied clinically. It is recorded by the People’s Republic of 2015 Edition of Pharmacopoeia, and used extensively for acute cerebral infarction by activating blood circulation and removing blood stasis, which ultimately activates meridians and collaterals. Shuxuetong injection is used clinically for treating the acute phase of ischemic stroke, and had total sales of over $93 million in 2017 in China. Shuxuetong injection is composed of leech (Hirudo nipponica Whitman) and earthworm (Phertetima aspergillum) (Hu et al., 2009; Yin, 2011a; Liu and Qin, 2016). Until now, the main active components were considered to be peptides, glycopeptides, and oligosaccharides (Yin, 2011b; Liu et al., 2015). In this study, we investigated the protective effects and mechanisms of Shuxuetong injection on brain microvascular endothelial cells after exposure to oxygen-glucose deprivation/reperfusion (OGD/R) injury. Specifically, we focused on BBB damage, mitochondrial dysfunction, and inflammatory injury to provide a practical examination for the treatment of ischemic stroke.

Materials and Methods
Cell culture
The mouse brain endothelial cell line, bEnd.3, was purchased from ATCC (Manassas, VA, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium (Corning Laboratories, Corning, NY, USA), supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA), 100 U/mL penicillin, and 100 U/mL streptomycin (Hyclone Laboratories, Logan, UT, USA) at 37°C in a humidified atmosphere mixture of 5% CO₂ and 95% air. The medium was replaced every 2 days.

OGD/R injury model establishment and Shuxuetong injection intervention
To mimic cell impairment during ischemic injury in vitro, the previously published OGD/R model was used as described, albeit with some modification (Chen et al., 2014; Wang et al., 2014a, b). Briefly, confluent cells were washed twice with pre-warmed phosphate-buffered saline (PBS). The culture medium was replaced with glucose-free Dulbecco’s modified Eagle’s medium, transferred to an anaerobic chamber (Stemcell, Vancouver, BC, Canada), and flushed with a gas mixture of 95% N₂/5% CO₂ for 6 hours. After OGD, the medium was exchanged for Dulbecco’s modified Eagle’s medium with high glucose in a humidified atmosphere with 95% air and 5% CO₂ at 37°C for 18-hour reoxygenation and glucose restoration. Controls were incubated with high-glucose Dulbecco’s modified Eagle’s medium in a normal atmosphere for 24 hours. OGD/R cells were harvested at 24 hours. Shuxuetong injection was diluted with Dulbecco’s modified Eagle’s medium before use in experiments. The effective concentration of Shuxuetong injection was separately diluted 32-, 64-, and 128-times, and added to cells during OGD/R.

Cell viability assay
The Cell Counting Kit-8 assay was used to evaluate cell viability, as previously described (Wu et al., 2013; Pan et al., 2017). Briefly, 1 × 10⁴/mL bEnd.3 cells were seeded into 96-well plates. They had reached 90% confluency at the time of OGD/R. After washing once with PBS, Cell Counting Kit-
8 solution (10%) was added to cultures and incubated for 1 hour in the incubator. Absorbance at 450 nm was measured using a microplate reader (Molecular Devices, Sunnyvale, CA, USA).

**Lactate dehydrogenase leakage assay**

Lactate dehydrogenase released from impaired cells was assessed using a diagnostic kit. bEnd.3 cells were plated into 96-well plates at 1 × 10⁴/mL, and harvested at 80–90% confluence. A small amount of culture medium (50 μL) was transferred into a new plate, and 50 μL of CytoTox-ONE Reagent (Dojindo, Shanghai, China) added and incubated for 10 minutes. Stop solution was then added. Fluorescence with an excitation wavelength of 490 nm was recorded (Molecular Devices).

**Intracellular reactive oxygen species levels and superoxide production assays**

Intracellular levels of reactive oxygen species production were measured as described previously (Wei et al., 2000). Detection of mitochondrial superoxide was measured using the fluorogenic probe, MitoSOX™ Red (Invitrogen, Carlsbad, CA, USA) (Won et al., 2015). bEnd.3 cells were subjected to OGD for 4 hours, then switched to a reperfusion condition and incubated for 60 minutes. Cells were loaded with 5 μM CM-H2DCFDA (Invitrogen) at 37°C for 10 minutes (reactive oxygen species levels), or 5 μM MitoSOX™ Red (Invitrogen) at 37°C for 30 minutes (superoxide production). Thereafter, cells were washed three times with PBS to remove residual probe. Cellular fluorescence intensity was measured at ex/em wavelengths of 488/525 nm and 510/580 nm, respectively, using a fluorescence microplate reader (Molecular Devices). Expression of fluorescence intensity was expressed as percentage of the control group. Images were captured using an inverted fluorescence microscope (TE200; Nikon, Tokyo, Japan).

**Transepithelial electrical resistance assay**

Integrity of monolayer bEnd.3 cells was measured using the transepithelial electrical resistance assay (Gao et al., 2016), according to the manufacturer’s instructions (Millipore, Billerica, MA, USA). Cells were seeded at 5 × 10⁴/mL in 200 μL complete Dulbecco’s modified Eagle’s medium in 24-well plates. Transepithelial electrical resistance value was detected using the Millicell ERS-Volt-Ohm Meter (Millipore).

**BBB permeability assay**

Function of *Shuxuetong* injection in regulating BBB permeability was tested in vitro using fluorescein isothiocyanate (FITC)-dextran and cell culture chamber Transwell inserts, as previously described (Shin et al., 2016). FITC-dextran (final concentration 1 mg/mL; average molecular mass 70 kDa; Sigma-Aldrich, St. Louis, MO, USA) was added to the upper culture medium at 37°C for 2 hours, followed by OGD/R. Next, 100 μL medium was collected from the lower compartment and fluorescence intensity measured using a microplate reader at 492/518 nm absorption/emission wavelengths.

**Real-time reverse transcription polymerase chain reaction (RT-PCR) assay**

After OGD for 6 hours and reperfusion for 18 hours, bEnd.3 cells were harvested from 6-well plates at 2 × 10⁵/mL. Total RNA was extracted using Trizol Reagent (Invitrogen). RNA samples (1 μg) were subsequently reverse-transcribed to cDNA using High Capacity cDNA Reverse Transcription Kits. Briefly, reactions were incubated in steps of 25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 minutes, and then held at 4°C. RT-PCR was performed using the ABI PRISM 7500 Sequence Detection System (Applied Biosystems, Foster City, CA, USA), with SYBR® Select Master Mix reagent and specific primers (Table 1). For each PCR, 20 μL total volumes consisted of 0.8 μL each of specific primer, 2 μg of cDNA template, and 10 μL of 2 × RT master mix. Thermal cycling conditions were: 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds, and extension at 60°C for 1 minute. Fluorescence signal was detected at the end of each cycle. mRNA expression levels were determined relative to a blank control after normalizing to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using the 2⁻ΔΔCT method. Analysis was performed in triplicates.

### Table 1 Primers used for real-time reverse transcription polymerase chain reaction

<table>
<thead>
<tr>
<th>Genes</th>
<th>Primer/probe</th>
<th>Primer/probe sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF-α</td>
<td>Forward primer</td>
<td>5′-GGG GGT GAT GCG TCC CCA AAG-3′</td>
</tr>
<tr>
<td></td>
<td>Reverse primer</td>
<td>5′-GGA GGG CTT TGG CCC GCT GG-3′</td>
</tr>
<tr>
<td>IL-1β</td>
<td>Forward primer</td>
<td>5′-GAC CTT TCA GGA TGA CGA CA-3′</td>
</tr>
<tr>
<td></td>
<td>Reverse primer</td>
<td>5′-AGC TCA TAT GGG TCC GCC AG-3′</td>
</tr>
<tr>
<td>IL-6</td>
<td>Forward primer</td>
<td>5′-CAG AGA TAC AAA GAA ATG ATG G-3′</td>
</tr>
<tr>
<td></td>
<td>Reverse primer</td>
<td>5′-ACT CCA GAA GAC CAG AGG AAA-3′</td>
</tr>
<tr>
<td>iNOS</td>
<td>Forward primer</td>
<td>5′-CAC CTT GGA GTT CAC CCA GT-3′</td>
</tr>
<tr>
<td></td>
<td>Reverse primer</td>
<td>5′-ACC ACT CTT GGG CGG CC-3′</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Forward primer</td>
<td>5′-CTT CAC CAC CAT GGA GAA GCC-3′</td>
</tr>
<tr>
<td></td>
<td>Reverse primer</td>
<td>5′-GGC ATG AGC TGT CAG GAT C-3′</td>
</tr>
</tbody>
</table>

GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; TNF: tumor necrosis factor; IL: interleukin; iNOS: inducible nitric oxide synthase.

**Western blot assay**

bEnd.3 cells were lysed in the presence of a protease inhibitor (Beyotime, Shanghai, China), and subsequently centrifuged at 12,000 r/min for 30 minutes at 4°C. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and then transferred onto polyvinylidene fluoride membranes (Millipore, Bedford, MA, USA). Membranes were blocked with 5% non-fat milk, followed by 4°C incubation overnight with anti-capase-3 (rabbit, polyclonal antibody, 1:1000; Abcam, Cambridge, MA, USA), anti-vascular cell adhesion molecule-1 (rabbit, polyclonal antibody, 1:1000; Abcam), anti-intercellular adhesion molecule-1 (mouse, monoclonal antibody, 1:1000; Abcam), anti-caspase-3 (rabbit, monoclonal antibody, 1:1000; CST), anti-VEGF antibody (rabbit, monoclonal antibody, 1:1000; Abcam), anti-cleaved caspase-3 (rabbit, monoclonal antibody, 1:800; CST, Beverly, MA, USA), anti-B-cell lymphoma 2 (Bcl-2) (rabbit, monoclonal antibody, 1:1000; CST), anti-Bcl-2 (mouse, monoclonal antibody, 1:1000; CST), anti-Bcl-2 (rabbit, monoclonal antibody, 1:1000; CST), anti-Bcl-2 (mouse, monoclonal antibody, 1:1000; CST).
anti-phosphorylated-(p)-ERK (rabbit, monoclonal antibody, 1:1000; CST), anti-ERK (rabbit, monoclonal antibody, 1:1000; CST), anti-NF-kB p65 (rabbit, monoclonal antibody, 1:1000; CST), anti-I kappa B alpha (IκBα) (rabbit, monoclonal antibody, 1:1000; CST), anti-p-IκBα (rabbit, monoclonal antibody, 1:1000; CST), anti-I kappa B kinase (IKK) (rabbit, monoclonal antibody, 1:1000; CST), anti-p-IKK antibody (rabbit, monoclonal antibody, 1:1000; CST), anti-PI3K antibody (mouse, monoclonal antibody, 1:1000; Invitrogen), and anti-VOZ-1 antibody (rabbit, polyclonal antibody, 1:1000; Millipore). β-Actin (rabbit, monoclonal antibody, 1:4000; CST) and anti-lamin-B1 antibody (rabbit, monoclonal antibody, 1:1000; Abcam) served as internal references. Membranes were incubated with the corresponding secondary antibodies: FITC-conjugated anti-mouse IgG (1:10,000; Zhongshan Company, Beijing, China) or FITC-conjugated anti-rabbit IgG (1:10,000; Zhongshan Company) for 1 hour at room temperature. Signal was visualized by enhanced chemiluminescence (Millipore). Quantification of bands was performed from optical density values using the Quantity One analysis system (Bio-Rad, Hercules, CA, USA).

**Statistical analysis**

Data are expressed as mean ± SD. All data obtained from at least three repeated experiments were analyzed using IBM SPSS Version 21.0 (IBM SPSS Inc., Chicago, IL, USA). Comparisons between multiple groups were performed by one-way analysis of variance followed by the least significant difference test. A value of $P < 0.05$ was considered statistically significant.

**Results**

*Shuxuetong* injection attenuates cell death and affects apoptosis-related protein expression of bEnd.3 cells after OGD/R-induced injury

First, bEnd.3 cells were exposed to 6 hours of OGD followed by 18 hours of reperfusion. Cell viability was assessed by both Cell Counting Kit-8 assay and measurement of extracellular lactate dehydrogenase leakage. As shown in Figure 1A, cell viability after 6 hours of OGD/R was reduced compared with the control group ($P < 0.01$). Administration of *Shuxuetong* injection significantly attenuated OGD/R-induced cell death, with significantly increased cell viability at 1/32, 1/64, and 1/128 concentrations compared with the 6-hour OGD/R group (all $P < 0.01$). As shown in Figure 1B, leakage of lactate dehydrogenase increased in the OGD/R group compared with the control group ($P < 0.01$). Meanwhile, *Shuxuetong* injection (1/32, 1/64, and 1/128) significantly reduced lactate dehydrogenase leakage (all $P < 0.01$). As shown in Figure 1C & D, OGD/R markedly increased expression of cleaved caspase-3 protein ($P = 0.018$), while it significantly reduced lactate dehydrogenase leakage (all $P < 0.01$).

Figure 1 Effect of SXT on cell viability and apoptosis-related protein expression in bEnd.3 cells subjected to OGD/R. bEnd.3 cells subjected to 6-hour OGD followed by reperfusion for 18 hours were administered *Shuxuetong* injection at 1/32, 1/64, and 1/128 concentrations (diluted 32-, 64-, and 128-times). (A) Cell viability detected by Cell Counting Kit-8 assay was analyzed at 24 hours after OGD/R. (C, D) Cleaved caspase-3 and Bcl-2 protein expression detected by western blot assay was analyzed at 24 hours after OGD/R. Relative protein expression was expressed as optical density value relative to control group after normalizing to GAPDH optical density value. Data are expressed as the mean ± SD (mean from three independent experiments, one-way analysis of variance followed by the least significant difference test). *P < 0.05, vs. control group; #P < 0.05, vs. OGD/R group (n = 6). SXT: *Shuxuetong* injection; OGD/R: oxygen-glucose deprivation/reperfusion; LDH: lactate dehydrogenase; GAPDH: glyceraldehyde-3-phosphate dehydrogenase.
was significantly attenuated by Shuxuetong injection treatment ($P < 0.05$ with 1/32 and 1/64 concentrations) (Figure 1C). Bcl-2 protein expression was reduced in the OGD/R group compared with the control group ($P = 0.021$), and significantly increased with Shuxuetong injection treatment ($P < 0.05$ with 1/32 concentration) (Figure 1D).

Further, we observed morphological changes after OGD/R injury. Consequently, after OGD for 6 hours and reperfusion for 18 hours, some bEnd.3 cells displayed shrinking bodies, and overall cells were sparse in the OGD/R group compared with the control group. However, Shuxuetong injection treatment at different concentrations (1/32, 1/64, and 1/128) attenuated OGD/R-induced injury to cellular morphology. Specifically, cells exhibited relatively good adherence compared with the OGD/R group (Figure 2).

**Shuxuetong injection reduces reactive oxygen species and mitochondrial superoxide production of bEnd.3 cells after OGD/R-induced injury**

Reactive oxygen species and mitochondrial superoxide levels were measured using DCFH-DA and MitoSOX Red reagents to determine whether Shuxuetong injection can exert a protective effect by inhibiting oxidative stress. bEnd.3 cells were exposed to 4 hours of OGD followed by reperfusion for 1 hour. As shown in Figure 3A & B, production of reactive oxygen species and mitochondrial superoxide in cells was increased (both $P < 0.01$) compared with controls. Administration of Shuxuetong injection significantly attenuated reactive oxygen species levels and mitochondrial superoxide production compared with the OGD/R group (all $P < 0.05$) (Figure 3C & D).

**Figure 2 Change in morphology of bEnd.3 cells treated with different concentrations of SXT followed by OGD/R.**

(A) Control group; (B) OGD/R group; (C–E) SXT at concentrations of 1/32, 1/64, and 1/128 (diluted 32-, 64-, and 128-times) with OGD injury for 6 hours and reperfusion for 18 hours. bEnd.3 cells displayed normal cell morphology in the control group (A), while cells were sparse with shrinking bodies in the model group (B). Treatment with SXT at different concentrations (1/32, 1/64, and 1/128) (C–E) resulted in relatively good adherence compared with cells in the model group. Scale bar: 100 μm. SXT: Shuxuetong injection; OGD/R: oxygen-glucose deprivation/reperfusion.

**Figure 3 Effect of SXT on ROS and mitochondrial peroxide production in bEnd.3 cells subjected to OGD/R.**

(A, B) Intracellular ROS levels (A) and mitochondrial superoxide levels (B) detected by fluorescence analysis. Intracellular ROS levels or mitochondrial superoxide levels were expressed as fluorescence intensity percentage of control group. Data are expressed as the mean ± SD (mean from three independent experiments; one-way analysis of variance followed by the least significant difference test). *$P < 0.05$, vs. control group; **$P < 0.05$ vs. OGD/R group ($n = 6$). (C, D) Representative images of ROS (green) (C) and MitoSOX™ Red (red) (D). Scale bars: 100 μm. SXT: Shuxuetong injection; OGD/R: oxygen-glucose deprivation/reperfusion; ROS: reactive oxygen species.
**Shuxuetong injection attenuates inflammation injury in bEnd.3 cells after OGD/R-induced injury**

OGD/R injury can trigger inflammation and induce various inflammatory mediators (Moskowitz et al., 2010). Next, we examined gene expression of proinflammatory cytokines such as TNF-α, interleukin (IL)-6, IL-1β, and inducible nitric oxide synthase by RT-PCR, and detected expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by western blot assay. Our other results (i.e., reactive oxygen species levels, mitochondrial superoxide levels, and transepithelial electrical resistance) clearly show a dose-response relationship with *Shuxuetong* injection. Thus, an optimal concentration (1/32) was chosen to examine mRNA levels. Although only one concentration was used, our data still suggests that *Shuxuetong* injection inhibits expression of inflammatory factors in bEnd.3 cells subjected to OGD/R injury. Accordingly, our results showed that *Shuxuetong* injection suppresses expression of intercellular adhesion molecule-1 (P < 0.05 at 1/64 concentration) and vascular cell adhesion molecule-1 (P < 0.05 with all three concentrations). Furthermore, expression of TNF-α, IL-6, IL-1β, and mRNA was remarkably increased after OGD/R-induced injury compared with controls (all P < 0.05). This increasing trend of inflammatory factors was inhibited by *Shuxuetong* injection at a concentration of 1/32 (all P < 0.05). Altogether, these data suggest that *Shuxuetong* injection inhibits expression of inflammatory factors in bEnd.3 cells subjected to OGD/R injury (Figure 4).

**Shuxuetong injection attenuates BBB dysfunction in bEnd.3 cells after OGD/R-induced injury**

To examine BBB integrity and permeability of monolayer bEnd.3 cells, the transepithelial electrical resistance assay and FITC-dextran assay were used, respectively. As shown in Figure 5, transepithelial electrical resistance was decreased to 59.26 ± 4.66% after OGD/R-induced injury compared with the control group (P < 0.01). Administration with *Shuxuetong* injection significantly increased transepithelial electrical resistance to 120.43 ± 5.22%, 114.30 ± 3.74%, and 113.67 ± 4.29% at concentrations of 1/32, 1/64, and 1/128, respectively, compared with the OGD/R group (all P < 0.01). As shown in Figure 3B, FITC-dextran concentration detected by cell culture chamber Transwell inserts increased to 143.69 ± 8.36% after OGD/R-induced injury compared with the control group (P < 0.01). Correspondingly, *Shuxuetong* injection reduced FITC-dextran concentration (P < 0.05 with 1/32 and 1/64 concentrations). These results suggest that *Shuxuetong* injection can protect bEnd.3 cells from damage by protecting the BBB.

**Shuxuetong injection improves expression of tight junction proteins in bEnd.3 cells after OGD/R-induced injury**

Aside from detecting BBB integrity and permeability, we also investigated the effect of *Shuxuetong* injection on expression of tight junction proteins after OGD/R injury. Compared with the control group, OGD/R visibly decreased expression of claudin-5, occludin, and ZO-1 in bEnd.3 cells (all P < 0.05). Administration of *Shuxuetong* injection significantly increased expression of claudin-5 (all P < 0.05), occludin (all P < 0.05), and ZO-1 (P < 0.05 with concentrations of 1/32 and 1/64) (Figure 6). These results show that *Shuxuetong* injection protects tight junction protein degradation following OGD/R injury.

**Shuxuetong injection inhibits activation of NF-κB in bEnd.3 cells after OGD/R injury**

To further investigate whether NF-κB transcription factors are involved in the protective effect of *Shuxuetong* injection against OGD/R injury, we measured translocation of NF-κB p65 and p-IκBα and p-IKK changes in bEnd.3 cells after OGD, with or without *Shuxuetong* injection treatment. Western blot assay results showed significantly increased protein levels of nuclear NF-κB p65, and p-IκBα and IKK phosphorylation levels in bEnd.3 cells after OGD/R treatment compared with the control group (all P < 0.05). This tendency was substantially reduced in bEnd.3 cells by administration of *Shuxuetong* injection at concentrations of 1/32, 1/64, and 1/128. Significance was detected for protein levels of nuclear NF-κB p65 (P < 0.05 at 1/64 concentration) and phosphorylation levels of IκBα (P < 0.05 at 1/32 concentration) and IKK (P < 0.05 at 1/64 and 1/128 concentrations). Total protein levels of NF-κB p65 showed no obvious change in bEnd.3 cells induced by OGD/R (P > 0.05) (Figure 7). NF-κB p65 translocates from the cytoplasm to nucleus. Thus, these results suggest that *Shuxuetong* injection inhibits activation of the NF-κB pathway.

**Shuxuetong injection decreases VEGF and p-ERK1/2 expression after OGD/R-induced injury**

OGD/R induces destruction or rearrangement of tight junctions, which further leads to an increase in BBB permeability. Factors involved include levels of signaling molecules such as pERK1/2 and the downstream molecule VEGF. bEnd.3 cells were exposed to 6-hour OGD and 18-hour reperfusion. Expression of VEGF protein and p-ERK1/2 were determined. As shown in Figure 8, expression of VEGF (P = 0.04) and phosphorylation of ERK1/2 (P = 0.041) were increased in the OGD/R group compared with the control group, and this increase was reversed by *Shuxuetong* injection. These results show that OGD/R-induced BBB disruption and the subsequent effect of *Shuxuetong* injection are associated with regulating signaling molecules of VEGF (all P < 0.05) and p-ERK1/2 (P < 0.05 with 1/32 and 1/128 concentrations).

**Discussion**

*Shuxuetong* injection is a traditional Chinese medicine that contains leech (*Hirudo nipponica Whitman*) and earthworm (*Phereutis aspergillum*), and is approved by the Chinese National Drug Administration. The manufacturing technology involves impregnating leeches and earthworms, which are then chopped and homogenized into slices, and repeatedly frozen. Afterwards, the slices are centrifuged and ultrafiltrated using freeze-thaw fluid to obtain a rough fil-
Shuxuetong injection is not very distinct, while Figure injection reduces reactive oxygen species and mitochondrial superoxide production, and inflammatory cytokine secretion. Therefore, these increases decreased after Shuxuetong injection treatment.

Several assumptions have been proposed to explain the underlying mechanisms of BBB dysfunction via expression of tight junction proteins after OGD/R injury. For example, upregulation of VEGF and ERK1/2 and activation of the NF-kB signaling pathway have been suggested (Figure 9) (Coisne et al., 2007; Kuhlmann et al., 2009; Blum et al., 2012; Engelhardt et al., 2014). ERK1/2 phosphorylation participates in degradation of tight junction protein levels in cerebral microvascular endothelial cells after ischemic stimuli (Shin et al., 2015b). Activation of VEGF is associated with tight junction protein levels in brain endothelial cells under chemical hypoxia in vitro (Shin et al., 2015a). Upregulation of VEGF expression can be induced by cerebral ischemia reperfusion injury, which is a key regulator for increasing BBB permeability (Young et al., 2004), while inhibition of VEGF expression can reduce BBB damage (Zhang et al., 2000). Protein levels of VEGF were increased following by increasing pERK1/2 expression, and could be inhibited by the ERK1/2 inhibitor, U0126, after ischemic injury in neonatal rat brain, suggesting that ERK1/2 participates in regulation of VEGF levels (Li et al., 2008). In contrast, changes of VEGF in brain endothelial cells after OGD/R exposure were dependent on ERK1/2 activation (Narasimhan et al., 2009). These results suggest that the preventative effect of Shuxuetong injection on degradation of tight junction proteins is associated with mechanisms underlying VEGF and p-ERK1/2 expression.

In summary, Shuxuetong injection reduces reactive oxygen species and mitochondrial superoxide production, inhibits inflammatory cytokine expression, and protects against BBB leakage by protecting tight junction protein expression levels. A possible mechanism may be that Shuxuetong injection can regulate NF-kB, VEGF, and ERK1/2 levels, and consequently exert a protective effect on BBB dysfunction in cerebral microvascular endothelial cells exposed to OGD/R injury. However, our study has limitations. For example, the dose-effect relationship of Shuxuetong injection is not very distinct, while the effective component(s) of Shuxuetong injection are still not clear. In follow-up experiments, it is necessary to investigate the effect of Shuxuetong injection on the protective effect of cerebral ischemia, as well as the corresponding dose-effect relationship. Pharmacology organically combines with drug chemistry, drug analysis, and other disciplines. This study clarifies the effective material basis of Shuxuetong injection to provide an experimental basis for its clinical application.

Author contributions: All authors contributed to conception and design of this study, performed the experiments, participated in data collection and analysis, contributed to preparation of manuscript, and approved the final version of the paper.

Conflicts of interest: The authors declare having no conflicts of interest pertinent to the current study and manuscript.

Financial support: This study was supported in part by the Nation-
Shuxuetong injection protects cerebral microvascular endothelial cells against oxygen-glucose deprivation reperfusion. Neural Regen Res 14(5):783-793. doi:10.4103/1673-5374.249226


Cells subjected to 6-hour OGD followed by reperfusion for 18 hours were administered Shuxuetong injection at 1/32, 1/64, and 1/128 concentrations (diluted 32-, 64-, and 128-times). (A, B) ICAM-1 and VCAM-1 protein expression levels were detected by western blot assay. Relative protein expression was expressed as optical density value relative to control group after normalizing to β-actin optical density value. (C–F) iNOS, TNF-α, IL-1β, and IL-6 mRNA expression levels were detected by real-time polymerase chain reaction. mRNA expression levels were determined relative to a blank control after normalizing to GAPDH using the 2−ΔΔCT method. Data are expressed as the mean ± SD (mean from three independent experiments; one-way analysis of variance followed by the least significant difference test). *P < 0.05, vs. control group; #P < 0.05, vs. OGD/R group (n = 3). SXT: Shuxuetong injection; OGD/R: oxygen-glucose deprivation/reperfusion; ICAM-1: intercellular adhesion molecule-1; VCAM-1: vascular cell adhesion molecule-1; TNF: tumor necrosis factor; IL: interleukin; iNOS: inducible nitric oxide synthase; GAPDH: glyceraldehyde-3-phosphate dehydrogenase.

Cells subjected to 6-hour OGD followed by reperfusion for 18 hours were administered Shuxuetong injection at 1/32, 1/64, and 1/128 concentrations (diluted 32-, 64-, and 128-times). (A) TEER values in monolayer bEnd.3 cells were detected using a cell resistance meter. (B) Quantification of FITC-dextran values detected by a microplate reader to measure blood-brain barrier permeability. Data are expressed as the mean ± SD (mean from three independent experiments; one-way analysis of variance followed by the least significant difference test). *P < 0.05, vs. control group; #P < 0.05, vs. OGD/R (n = 6). SXT: Shuxuetong injection; OGD/R: oxygen-glucose deprivation/reperfusion; TEER: transepithelial electrical resistance; FITC: fluorescein isothiocyanate.

Cells subjected to 6-hour OGD followed by reperfusion for 18 hours were administered Shuxuetong injection at 1/32, 1/64, and 1/128 concentrations (diluted 32-, 64-, and 128-times). Protein expression levels of (A) claudin-5, (B) occludin, and (C) ZO-1 levels were measured by western blot assay. Relative protein expression was expressed as optical density value relative to control group after normalizing to β-actin optical density value. Data are expressed as the mean ± SD (mean from three independent experiments; one-way analysis of variance followed by the least significant difference test). *P < 0.05, vs. control group; #P < 0.05, vs. OGD/R group (n = 6). SXT: Shuxuetong injection; OGD/R: oxygen-glucose deprivation/reperfusion; zo-1: zonula occludens-1.
Cells subjected to 6-hour OGD followed by reperfusion for 18 hours were administered Shuxuetong injection at 1/32, 1/64, and 1/128 concentrations (diluted 32-, 64-, and 128-times). Protein levels of nuclear NF-κB p65 (A), cytoplasmic NF-κB p65 (B), phosphorylated IκBα (C), and phosphorylated IKK (D) were detected by western blot assay. NF-κB p65 protein in the cytoplasm and nucleus were expressed as a relative ratio of target protein to β-actin or lamin-B respectively. Protein levels of phosphorylated IκBα and phosphorylated IKK were expressed as a relative ratio of target protein to IκBα or IKK, respectively. Data are expressed as the mean ± SD (mean from three independent experiments; one-way analysis of variance followed by the least significant difference test). #P < 0.05, vs. control group; *P < 0.05, vs. OGD/R group (n = 3). SXT: Shuxuetong injection; OGD/R: oxygen-glucose deprivation/reperfusion; NF-κB: nuclear factor kappa B; IκBα: inhibitor of kappa B; IKK: Iκappa B kinase.

Cells subjected to 6-hour OGD followed by reperfusion for 18 hours were administered Shuxuetong injection at 1/32, 1/64, and 1/128 concentrations (diluted 32-, 64-, and 128-times). Protein expression levels of VEGF (A) and p-ERK1/2 (B) levels were measured by western blot assay. Relative VEGF protein expression was expressed as optical density value relative to the control group after normalizing to β-actin optical density value. Relative p-ERK1/2 protein expression was expressed as optical density value relative to ERK1/2 optical density value. Data are expressed as mean ± SD (mean from three independent experiments; one-way analysis of variance followed by least significant difference test). #P < 0.05, vs. control group; *P < 0.05 vs. OGD/R group (n = 3). SXT: Shuxuetong injection; OGD/R: oxygen-glucose deprivation/reperfusion; VEGF: vascular endothelial growth factor; ERK1/2: extracellular signal regulated protein kinase 1/2; p-ERK1/2: phosphorylated extracellular signal regulated protein kinase 1/2.
al Natural Science Foundation of China, No. 81573644 (to LMH), 81573733 (to SWX), the Tianjin 134 Innovative Team Project, China (to HW); the National Major Science and Technology Project of China, No. 2012ZX09101020-004 (to SWX); the Science and Technology Plan Project of Tianjin of China (General Project), No. 14CYJB029900 (to SWX); the National International Science and Technology Cooperation Project of China, No.2015DFA30430 (to HW); the Key Program of the Natural Science Foundation of Tianjin of China, No.16JCZDJC36300 (to HW); the Scientific Research and Technology Development Plan Project of Guangxi Zhuang Autonomous Region of China, No. 14125008-2-5 (to SWX). The funders had no roles in the study design, conduction of experiment, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Data sharing statement: Datasets analyzed during the current study are available from the corresponding author on reasonable request.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Open peer reviewer: Paola Bagnoli, Università degli Studi di Pisa, Italy.

Additional file: Open peer review report 1.

References


P-Reviewer: Bargno P; C-Editor: Zhao M; S-Editors: Yu J, Li CH; L-Editors: James R, Hindle A, Qiu Y, Song LP; T-Editor: Liu XL